Arrowhead Research ARWR Increase (Decrease) in Prepaid Expense and Other Assets

Increase (Decrease) in Prepaid Expense and Other Assets at other companies

ALN

Alnylam PharmaceuticalsALNY

——

BridgeBio PharmaBBIO

——

Madrigal Pharmaceuticals, Inc.MDGL

——

AbbVieABBV

——

Medpace Holdings, Inc.MEDP

——

IncyteINCY

——

Other financials

Income statement

See full

Revenue$73.7M-86.4%

Operating income-$141.3M-137%

Net income-$132.7M-136%

EPS (diluted)-$0.93-134%

Balance sheet

See full

Cash & equivalents$188.5M+1.5%

Total debt$107.9M-5.6%

Total equity$614.0M-10.1%

Total assets$2.3B+44.2%

Cash flow

See full

Operating cash flow$84.4M-81.6%

CapEx$2.6M-51.6%

Free cash flow$81.9M-82.0%

Valuation

See full

Market cap$11.52B+402%

Enterprise value$11.44B+418%

P/S18.5×+14.3×

Profitability

See full

Operating margin-35.7%+63.6pp

Net margin-48.4%+240pp

FCF margin1.8%+0.9pp

Returns & leverage

See full

Return on equity-46.4%+341pp

Debt / equity0.2×0.0×

Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Arrowhead Research’s 10-Q, filed February 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's increase (decrease) in prepaid expense and other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arrowhead Research's increase (decrease) in prepaid expense and other assets?: Arrowhead Research (ARWR) reported increase (decrease) in prepaid expense and other assets of $13.18M in Q4 2025.
How has Arrowhead Research's increase (decrease) in prepaid expense and other assets changed year-over-year?: Arrowhead Research's increase (decrease) in prepaid expense and other assets increased by 2126.7% year-over-year, from $592K to $13.18M.